Skip to main content
. Author manuscript; available in PMC: 2011 Jul 12.
Published in final edited form as: Vaccine. 2010 May 16;28(31):4875–4879. doi: 10.1016/j.vaccine.2010.05.002

Table 1.

Key Model Inputs

Parameter Age Group Sources
0 to 5 Months 6 to 23 Months 2 to 4.9 Years 5 to 18 Years 19 to 24 Years 25 to 49 Years 50 to 64 Years 65 Years +
United States Population (millions) 2.10 6.30 12.60 53.02 29.66 106.31 55.18 38.87 [29]
DC Metropolitan Region Population 0.052 0.16 0.32 1,52 0.48 3.00 1.16 0.73 [29]
H1N1 Hospitalization Ratio per 100 Cases 0.70 0.70 0.70 0.27 0.27 0.56 1.06 1.55 [30]
H1N1 Case Fatality Ratio per 100 Cases 0.022 0.022 0.022 0.009 0.136 0.136 0.136 0.028 [30]
Residual Remote H1N1 Immunity (%) 0.0% 0.0% 0.0% 2.0% 2.0% 6.0% 9.0% 34.0% [23]
Percent At-Risk (Immunocompromised) 0.01% 0.02% 0.03% 0.24% 0.68% 1.31% 3.27% 6.14% [31, 32]
Percent At-Risk (> 1 chronic condition) 1.5% 4.2% 8.83% 11.68% 12.35% 15.70% 30.56% 47.01% [32]
Live Attenuated Virus Vaccine Efficacy N/A N/A 0.25 (1-dose) 0.7 (2-doses) 0.83 0.83 0.83 N/A N/A 33, 34]
Inactivated Virus Vaccine Efficacy (Novartis) N/A N/A N/A 0.78 0.78 0.78 0.73 0.5 [33, 34]
Inactivated Virus Vaccine Efficacy (GSK) N/A N/A N/A N/A 0.78 0.78 0.73 0.5 [33, 34]
Inactivated Virus Vaccine Efficacy (CSL) N/A N/A N/A N/A 0.78 0.78 0.73 0.5 [33, 34]
Inactivated Virus Vaccine Efficacy (Sanofi) N/A 0.15(1-dose) 0.5(2-doses) 0.25(1-dose) 0.7(2-doses) 0.78 0.78 0.78 0.73 0.5 [33, 34]